Annual Accounts Receivable
$35.96 M
+$1.33 M+3.85%
31 December 2023
Summary:
Anika Therapeutics annual accounts receivable is currently $35.96 million, with the most recent change of +$1.33 million (+3.85%) on 31 December 2023. During the last 3 years, it has risen by +$11.86 million (+49.20%). ANIK annual accounts receivable is now at all-time high.ANIK Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$28.36 M
-$5.42 M-16.04%
30 September 2024
Summary:
Anika Therapeutics quarterly accounts receivable is currently $28.36 million, with the most recent change of -$5.42 million (-16.04%) on 30 September 2024. Over the past year, it has dropped by -$6.33 million (-18.24%). ANIK quarterly accounts receivable is now -22.81% below its all-time high of $36.74 million, reached on 30 June 2023.ANIK Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ANIK Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +3.9% | -18.2% |
| 3 y3 years | +49.2% | -12.3% |
| 5 y5 years | +73.1% | +18.7% |
ANIK Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +49.2% | -22.8% | at low |
| 5 y | 5 years | at high | +73.1% | -22.8% | +23.2% |
| alltime | all time | at high | +2901.8% | -22.8% | +2891.2% |
Anika Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $28.36 M(-16.0%) |
| June 2024 | - | $33.77 M(+5.3%) |
| Mar 2024 | - | $32.08 M(-10.8%) |
| Dec 2023 | $35.96 M(+3.9%) | $35.96 M(+3.7%) |
| Sept 2023 | - | $34.68 M(-5.6%) |
| June 2023 | - | $36.74 M(+19.9%) |
| Mar 2023 | - | $30.63 M(-11.5%) |
| Dec 2022 | $34.63 M(+16.0%) | $34.63 M(+1.3%) |
| Sept 2022 | - | $34.17 M(+6.2%) |
| June 2022 | - | $32.17 M(+9.8%) |
| Mar 2022 | - | $29.31 M(-1.8%) |
| Dec 2021 | $29.84 M(+23.8%) | $29.84 M(-7.8%) |
| Sept 2021 | - | $32.35 M(+9.9%) |
| June 2021 | - | $29.43 M(+11.0%) |
| Mar 2021 | - | $26.51 M(+10.0%) |
| Dec 2020 | $24.10 M(+4.4%) | $24.10 M(+4.8%) |
| Sept 2020 | - | $23.01 M(-4.5%) |
| June 2020 | - | $24.09 M(-14.3%) |
| Mar 2020 | - | $28.10 M(+21.8%) |
| Dec 2019 | $23.08 M(+11.1%) | $23.08 M(-3.4%) |
| Sept 2019 | - | $23.89 M(+3.5%) |
| June 2019 | - | $23.07 M(+26.3%) |
| Mar 2019 | - | $18.27 M(-12.1%) |
| Dec 2018 | $20.77 M(-12.8%) | $20.77 M(+0.0%) |
| Sept 2018 | - | $20.77 M(-11.2%) |
| June 2018 | - | $23.39 M(+27.9%) |
| Mar 2018 | - | $18.29 M(-23.2%) |
| Dec 2017 | $23.82 M(-13.7%) | $23.82 M(+0.1%) |
| Sept 2017 | - | $23.80 M(-21.8%) |
| June 2017 | - | $30.45 M(+44.5%) |
| Mar 2017 | - | $21.08 M(-23.6%) |
| Dec 2016 | $27.60 M(+27.5%) | $27.60 M(+26.4%) |
| Sept 2016 | - | $21.83 M(-11.2%) |
| June 2016 | - | $24.60 M(+66.2%) |
| Mar 2016 | - | $14.80 M(-31.7%) |
| Dec 2015 | $21.65 M(+26.2%) | $21.65 M(-7.4%) |
| Sept 2015 | - | $23.38 M(+22.0%) |
| June 2015 | - | $19.17 M(+19.6%) |
| Mar 2015 | - | $16.03 M(-6.6%) |
| Dec 2014 | $17.15 M(-8.5%) | $17.15 M(-15.0%) |
| Sept 2014 | - | $20.17 M(+4.9%) |
| June 2014 | - | $19.23 M(+16.8%) |
| Mar 2014 | - | $16.47 M(-12.1%) |
| Dec 2013 | $18.74 M(-12.7%) | $18.74 M(+13.6%) |
| Sept 2013 | - | $16.50 M(-13.5%) |
| June 2013 | - | $19.07 M(+29.0%) |
| Mar 2013 | - | $14.78 M(-31.1%) |
| Dec 2012 | $21.46 M | $21.46 M(+31.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $16.34 M(-7.6%) |
| June 2012 | - | $17.69 M(+4.1%) |
| Mar 2012 | - | $17.00 M(-1.8%) |
| Dec 2011 | $17.31 M(+16.8%) | $17.31 M(-2.4%) |
| Sept 2011 | - | $17.73 M(+4.2%) |
| June 2011 | - | $17.02 M(+36.3%) |
| Mar 2011 | - | $12.49 M(-15.7%) |
| Dec 2010 | $14.82 M(+25.8%) | $14.82 M(+0.6%) |
| Sept 2010 | - | $14.73 M(-2.2%) |
| June 2010 | - | $15.06 M(+18.5%) |
| Mar 2010 | - | $12.71 M(+7.9%) |
| Dec 2009 | $11.78 M(+117.4%) | $11.78 M(+47.6%) |
| Sept 2009 | - | $7.98 M(+23.6%) |
| June 2009 | - | $6.46 M(-0.4%) |
| Mar 2009 | - | $6.48 M(+19.6%) |
| Dec 2008 | $5.42 M(-6.5%) | $5.42 M(-17.0%) |
| Sept 2008 | - | $6.53 M(+10.1%) |
| June 2008 | - | $5.93 M(+80.3%) |
| Mar 2008 | - | $3.29 M(-43.2%) |
| Dec 2007 | $5.80 M(+65.2%) | $5.80 M(+16.7%) |
| Sept 2007 | - | $4.97 M(-26.4%) |
| June 2007 | - | $6.75 M(+124.5%) |
| Mar 2007 | - | $3.01 M(-14.3%) |
| Dec 2006 | $3.51 M(+69.9%) | $3.51 M(+27.7%) |
| Sept 2006 | - | $2.75 M(-0.7%) |
| June 2006 | - | $2.77 M(+23.5%) |
| Mar 2006 | - | $2.24 M(+8.4%) |
| Dec 2005 | $2.07 M(-12.2%) | $2.07 M(+31.9%) |
| Sept 2005 | - | $1.57 M(-42.9%) |
| June 2005 | - | $2.74 M(+7.3%) |
| Mar 2005 | - | $2.56 M(+8.7%) |
| Dec 2004 | $2.35 M(+65.7%) | $2.35 M(-23.4%) |
| Sept 2004 | - | $3.08 M(+81.6%) |
| June 2004 | - | $1.69 M(-43.1%) |
| Mar 2004 | - | $2.98 M(+109.4%) |
| Dec 2003 | $1.42 M(+18.6%) | $1.42 M(-25.6%) |
| Sept 2003 | - | $1.91 M(-9.3%) |
| June 2003 | - | $2.10 M(+122.0%) |
| Mar 2003 | - | $948.00 K(-20.9%) |
| Dec 2002 | $1.20 M(-46.5%) | $1.20 M(-48.0%) |
| Sept 2002 | - | $2.30 M(+3.3%) |
| June 2002 | - | $2.23 M(+8.5%) |
| Mar 2002 | - | $2.05 M(-8.4%) |
| Dec 2001 | $2.24 M(+32.4%) | $2.24 M(+11.9%) |
| Sept 2001 | - | $2.00 M(+66.1%) |
| June 2001 | - | $1.21 M(-3.6%) |
| Mar 2001 | - | $1.25 M(-26.1%) |
| Dec 2000 | $1.69 M(-19.4%) | $1.69 M(-19.4%) |
| Dec 1999 | $2.10 M | $2.10 M |
FAQ
- What is Anika Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Anika Therapeutics?
- What is Anika Therapeutics annual accounts receivable year-on-year change?
- What is Anika Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Anika Therapeutics?
- What is Anika Therapeutics quarterly accounts receivable year-on-year change?
What is Anika Therapeutics annual accounts receivable?
The current annual accounts receivable of ANIK is $35.96 M
What is the all time high annual accounts receivable for Anika Therapeutics?
Anika Therapeutics all-time high annual accounts receivable is $35.96 M
What is Anika Therapeutics annual accounts receivable year-on-year change?
Over the past year, ANIK annual accounts receivable has changed by +$1.33 M (+3.85%)
What is Anika Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of ANIK is $28.36 M
What is the all time high quarterly accounts receivable for Anika Therapeutics?
Anika Therapeutics all-time high quarterly accounts receivable is $36.74 M
What is Anika Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, ANIK quarterly accounts receivable has changed by -$6.33 M (-18.24%)